Delineation of the intra-tumor microenvironment in a dynamic, spatiotemporal setting is critical for investigating the activity and efficacy of candidate oncology drugs. The majority of solid cancers contain unorganized, highly-complex microenvironments wherein a dysregulated phenotype impacts treatment outcomes at a personalized level.
Join this webinar to learn about a clinically-validated and fully human ex vivo platform technology which uses fresh patient material (tumor, autologous ligands and immune cells) to explore the mechanism of, and predict efficacy for, clinically-directed compounds across several drug classes.1
The platform affords many drug development and discovery applications, including:
- Optimal combination therapies – the prediction outcome system provides a standardized approach to the prioritization of the combinatorial strategies tested
- Mechanism of action – integrated phenotypic outcome and subsequent omic data can shed light on the potential mechanisms of action that underlie a response of interest
- Drug impact – the platform’s preservation of the tumor microenvironment, including the tumor immune compartment, can help hone immunomodulatory strategies
- Biomarker discovery – the tool’s predictive power can be leveraged to identify biomarkers that distinguish populations of responders from non-responders
- Indication prioritization – prioritization algorithms can be used to determine which tumor types will be best addressed by a lead candidate
- Parallel clinical trials – a flexible platform can be harnessed to rapidly assess differential response and resistance profiles within a patient population
Drugs that modulate the immune system have been shown to be very effective in some patients. In general, tumor infiltrating lymphocytes are required for the function of these drugs. A case study on the use of this ex vivo platform technology to understand the role of functional immune phenotypes when using a checkpoint inhibitor on patient tumor samples will be presented.
This webinar will explore how this platform can better enable your translational efforts (including mechanism of action and efficacy) and aid in advancing your highest potential candidate into successful clinical trials with high confidence.
1. Majumder B et al. Nature Comm., 6:6169:1-14 2015
Stefan Jellbauer, Ph.D., Technical Liaison at Mitra Biotech
Dr. Stefan Jellbauer is the Technical Liaison for Translational Applications and works with clients to craft custom solutions for their drug development needs. He supports the Biopharma Business Development side of Mitra Biotech. After 10 years in academic research, he joined Affymetrix/eBioscience, where he worked in the roles of Field Application Scientist and Technical Specialist with Affymetrix and Thermo Fisher Scientific. He joined Mitra Biotech in May 2018.
Dr. Jellbauer received his Ph.D. in Biology from Ludwig-Maximilians University in Munich (Germany), focusing on tumor vaccination. He completed his post-doctoral work at the University of California, Irvine studying mucosal immunology and host-pathogen interactions.Message Presenter
Who Should Attend?
Oncology program translational leads working with small molecules, biologics, and immuno-oncology drug candidates
What You Will Learn
Join this webinar to learn about a clinically-validated and fully human ex vivo platform which can help advance drug development. Applications include:
- Optimal combination therapies
- Mechanism of action
- Drug impact
- Biomarker discovery
- Indication prioritization
- Parallel clinical trials
Mitra Biotech Inc.
Mitra Biotech Inc. is a global leader in advancing truly personalized oncology treatment. The company’s CANscript™ platform recreates a patient’s own tumor microenvironment in vitro, measures multiple parameters to determine whether a tumor is responding to customer selected treatments, and then converts these parameters into a single score that predicts clinical response to each of the customer selected therapies.
CANscript delivers powerful, individualized treatment response predictions — with exceptionally high correlation to clinical outcomes — to inform patient-specific cancer treatment selection and support more effective and efficient cancer drug development.
Founded in 2010, Mitra is headquartered in Greater Boston and maintains a significant research and laboratory presence in Bengaluru, India.